Ganesh M Babulal1, Nupur Ghoshal2, Denise Head3, Elizabeth K Vernon2, David M Holtzman4, Tammie L S Benzinger5, Anne M Fagan4, John C Morris6, Catherine M Roe7. 1. Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO. Electronic address: babulalg@neuro.wustl.edu. 2. Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO. 3. Departments of Neurology, Washington University School of Medicine, St. Louis, MO; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO; Hope Center for Psychology, Washington University School of Medicine, St. Louis, MO. 4. Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO; Departments of Neurology, Washington University School of Medicine, St. Louis, MO; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO. 5. Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO; Hope Center for Radiology, Washington University School of Medicine, St. Louis, MO; Hope Center for Pathology and Immunology, Washington University School of Medicine, St. Louis, MO. 6. Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO; Departments of Neurology, Washington University School of Medicine, St. Louis, MO; Hope Center for Physical Therapy, Washington University School of Medicine, St. Louis, MO; Hope Center for Neurosurgery, Washington University School of Medicine, St. Louis, MO; Hope Center for Occupational Therapy, Washington University School of Medicine, St. Louis, MO. 7. Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO; Departments of Neurology, Washington University School of Medicine, St. Louis, MO.
Abstract
OBJECTIVES: To evaluate whether cerebrospinal fluid (CSF) and PET Pittsburgh Compound B (PiB) biomarkers of underlying Alzheimer disease (AD) pathology (β-amyloid42 [Aβ42], tau, phosphorylated tau181 [ptau181], tau/Aβ42, ptau181/Aβ42 and mean cortical binding potential [MCBP] for PET-PiB) predict changes in mood in cognitively normal older adults. SETTING: Knight Alzheimer's Disease Research Center (ADRC) at Washington University (WU). PARTICIPANTS: Participants, 65 years of age or older, were enrolled from longitudinal studies at the WU Knight ADRC. MEASUREMENTS: CSF, PET-PiB biomarkers, Clinical Dementia Rating (CDR), Mini-Mental State Examination (MMSE), Profile of Mood States-Short Form (POMS-SF), the Geriatric Depression Scale (GDS), and Neuropsychiatric Inventory Questionnaire (NPI-Q). RESULTS: Data from 118 participants at baseline and 66 participants at one-year follow-up were analyzed. CSF and PET biomarkers were not associated cross-sectionally with any mood disturbances at baseline (p > 0.05). Changes in mood as indicated by the total mood disturbance score on the POMS-SF, selected POMS-SF subscales, GDS, and NPI-Q scores from baseline to one-year follow-up were associated with (p < 0.05) CSF and PET-PiB biomarkers. There was no statistically significant decline in cognitive functioning. CONCLUSIONS: Generally, higher values of CSF and PET-PiB biomarkers are associated with more changes in mood in cognitively normal older adults. Further work is needed to understand the temporal development of mood changes over several years during the phase of preclinical AD. Evaluating mood as a noncognitive outcome may provide further insight into the development of preclinical AD in cognitively normal older adults.
OBJECTIVES: To evaluate whether cerebrospinal fluid (CSF) and PET Pittsburgh Compound B (PiB) biomarkers of underlying Alzheimer disease (AD) pathology (β-amyloid42 [Aβ42], tau, phosphorylated tau181 [ptau181], tau/Aβ42, ptau181/Aβ42 and mean cortical binding potential [MCBP] for PET-PiB) predict changes in mood in cognitively normal older adults. SETTING: Knight Alzheimer's Disease Research Center (ADRC) at Washington University (WU). PARTICIPANTS: Participants, 65 years of age or older, were enrolled from longitudinal studies at the WU Knight ADRC. MEASUREMENTS: CSF, PET-PiB biomarkers, Clinical Dementia Rating (CDR), Mini-Mental State Examination (MMSE), Profile of Mood States-Short Form (POMS-SF), the Geriatric Depression Scale (GDS), and Neuropsychiatric Inventory Questionnaire (NPI-Q). RESULTS: Data from 118 participants at baseline and 66 participants at one-year follow-up were analyzed. CSF and PET biomarkers were not associated cross-sectionally with any mood disturbances at baseline (p > 0.05). Changes in mood as indicated by the total mood disturbance score on the POMS-SF, selected POMS-SF subscales, GDS, and NPI-Q scores from baseline to one-year follow-up were associated with (p < 0.05) CSF and PET-PiB biomarkers. There was no statistically significant decline in cognitive functioning. CONCLUSIONS: Generally, higher values of CSF and PET-PiB biomarkers are associated with more changes in mood in cognitively normal older adults. Further work is needed to understand the temporal development of mood changes over several years during the phase of preclinical AD. Evaluating mood as a noncognitive outcome may provide further insight into the development of preclinical AD in cognitively normal older adults.
Authors: Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan Journal: Lancet Neurol Date: 2013-09-04 Impact factor: 44.182
Authors: John C Morris; Catherine M Roe; Elizabeth A Grant; Denise Head; Martha Storandt; Alison M Goate; Anne M Fagan; David M Holtzman; Mark A Mintun Journal: Arch Neurol Date: 2009-12
Authors: Helen Lavretsky; Prabha Siddarth; Vladimir Kepe; Linda M Ercoli; Karen J Miller; Alison C Burggren; Susan Y Bookheimer; Sung-Cheng Huang; Jorge R Barrio; Gary W Small Journal: Am J Geriatr Psychiatry Date: 2009-06 Impact factor: 4.105
Authors: G Li; I Sokal; J F Quinn; J B Leverenz; M Brodey; G D Schellenberg; J A Kaye; M A Raskind; J Zhang; E R Peskind; T J Montine Journal: Neurology Date: 2007-08-14 Impact factor: 9.910
Authors: Ganesh M Babulal; Suzie Chen; Monique M Williams; Jean-Francois Trani; Parul Bakhshi; Grace L Chao; Sarah H Stout; Anne M Fagan; Tammie L S Benzinger; David M Holtzman; John C Morris; Catherine M Roe Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Muhammad Haroon Burhanullah; JoAnn T Tschanz; Matthew E Peters; Jeannie-Marie Leoutsakos; Joshua Matyi; Constantine G Lyketsos; Milap A Nowrangi; Paul B Rosenberg Journal: Am J Geriatr Psychiatry Date: 2019-05-23 Impact factor: 4.105
Authors: Nancy J Donovan; Joseph J Locascio; Gad A Marshall; Jennifer Gatchel; Bernard J Hanseeuw; Dorene M Rentz; Keith A Johnson; Reisa A Sperling Journal: Am J Psychiatry Date: 2018-01-12 Impact factor: 18.112
Authors: Jennifer R Gatchel; Nancy J Donovan; Joseph J Locascio; Aaron P Schultz; J Alex Becker; Jasmeer Chhatwal; Kathryn V Papp; Rebecca E Amariglio; Dorene M Rentz; Deborah Blacker; Reisa A Sperling; Keith A Johnson; Gad A Marshall Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: A J Ehrenberg; A K Nguy; P Theofilas; S Dunlop; C K Suemoto; A T Di Lorenzo Alho; R P Leite; R Diehl Rodriguez; M B Mejia; U Rüb; J M Farfel; R E de Lucena Ferretti-Rebustini; C F Nascimento; R Nitrini; C A Pasquallucci; W Jacob-Filho; B Miller; W W Seeley; H Heinsen; L T Grinberg Journal: Neuropathol Appl Neurobiol Date: 2017-03-31 Impact factor: 8.090
Authors: Ganesh M Babulal; Sarah H Stout; Denise Head; David M Holtzman; Anne M Fagan; John C Morris; Catherine M Roe Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Ganesh M Babulal; Catherine M Roe; Sarah H Stout; Ganesh Rajasekar; Julie K Wisch; Tammie L S Benzinger; John C Morris; Beau M Ances Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472